Immunovia Full Year report 2019
“I am incredibly proud of the progress we made during 2019, especially in reaching the important milestone in December 2019 where we showed 95% accuracy for the upcoming commercialization of IMMray™ PanCan-d in diagnosing pancreatic cancer at a stage where it can still be operated on. This result opens the way for a significant improvement in care and an improved survival rate for patients suffering from this deadly disease. At Immunovia, we remain focused on introducing our blood-based test to the market in Q3 2020.With two milestones remaining – a verification study and a final validation